Medication law of Traditional Chinese Medicine patent compounds in the treatment of Alzheimer disease based on data mining
10.3760/cma.j.cn115398-20211111-00138
- VernacularTitle:基于数据挖掘的中药专利复方治疗阿尔茨海默病用药规律
- Author:
Shanshan LI
1
;
Min ZHAO
;
Jiangyan SUN
;
Jie ZHANG
;
Yuanyuan YAN
;
Zhihui CUI
;
Menglong SHI
Author Information
1. 河南中医药大学2019级硕士研究生，郑州 450046
- Keywords:
Alzheimer disease;
Compounds (TCD);
Data mining;
Cluster analysis;
Rules of medication
- From:
International Journal of Traditional Chinese Medicine
2023;45(2):220-226
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To analyze the medication law of Traditional Chinese Medicine (TCM) patent compounds for Alzheimer disease (AD) by using data mining method.Methods:The TCM compounds for the treatment of AD in the patent database were screened, and the frequency, clustering and association analysis were carried out with the help of TCM inheritance calculation platform, SPSS Statistics 21.0 and SPSS Modeler 18.0 software. The medication law was analyzed.Results:A total of 220 patent compounds were included, involving 361 kinds of Chinese materia medica; the top 10 high-frequency drugs were Acori Tatarinowii Rhizoma, Polygalae Radix, Ginseng Radix et Rhizoma, Chuanxiong Rhizoma, Astragali Radix, Lycii Fructus, Poria, Rehmanniae Radix PraeparataAngelicae Sinensis Radix, Salviae Miltiorrhizae Radix et Rhizoma; the most frequently used drugs were drugs for tonifying deficiency and promoting blood circulation to remove blood stasis; most of their properties belonged to warm, mild and cold; the tastes were mainly sweet, bitter and pungent; the meridians belonged to the five internal organs. 16 items of association data (4 combinations of two items and 12 combinations of three items) were obtained by association rule analysis, and the strongest correlation group was " Acori Tatarinowii Rhizoma- Polygalae Radix" and " Acori Tatarinowii Rhizoma- Chuanxiong Rhizoma- Polygalae Radix". Cluster analysis showed four prescription combinations and three pairs of drug compatibility, including the addition and subtraction structure of Kaixin Powder, Zuogui Pill, Bazhen decoction and so on. Conclusion:The core treatment principle of TCM patent compound treatment of AD is regulating and tonifying the five internal organs to treat its root, resolving phlegm and removing blood stasis to treat the symptoms, which accords with the theoretical basis of TCM in the treatment of AD, and can provide reference for clinical practice and new drug research and development.
